Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease

BACKGROUND: Tolvaptan (TV) is the first vasopressin-receptor antagonist approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). No publications report TV experience in real clinical practice during the first year of treatment. METHODS: A prospective study of an initial co...

Descripción completa

Detalles Bibliográficos
Autores principales: Naranjo, Javier, Borrego, Francisco, Rocha, José Luis, Salgueira, Mercedes, Martín-Gomez, Maria Adoración, Orellana, Cristhian, Morales, Ana, Vallejo, Fernando, Hidalgo, Pilar, Rodríguez, Francisca, Garófano, Remedios, González, Isabel, Esteban, Rafael, Espinosa, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557750/
https://www.ncbi.nlm.nih.gov/pubmed/36250074
http://dx.doi.org/10.3389/fmed.2022.987092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557750/
https://www.ncbi.nlm.nih.gov/pubmed/36250074
http://dx.doi.org/10.3389/fmed.2022.987092

Ejemplares similares